Clinical Trials Directory

Trials / Completed

CompletedNCT04879225

Menthol and Mint Experimental Tobacco Marketplace (ETM) Study

The Impact of Menthol and Mint E-liquid Bans on Menthol Cigarette Smokers

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Wake Forest University Health Sciences · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

Menthol cigarettes comprise almost one-third of the United States (US) market share and are disproportionately smoked by racial minorities. Tobacco control policies targeting menthol flavoring in tobacco could have significant public health outcomes, especially among black smokers. One key challenge of tobacco regulation is weighing the risks and benefits of potential policies across different populations (i.e., users and non-users). Tension arises between policies intended to prevent adolescent and young adult (AYA) tobacco initiation and those intended to reduce harm among current tobacco users. The availability of menthol e-liquids may be important for encouraging menthol cigarette smokers to switch to e- cigarettes, but mint e-liquids, which are appealing to AYA, may be unnecessary to facilitate switching. Including mint e-liquids in flavor bans but allowing menthol e-liquids to remain on the market as potential substitution products for menthol smokers may be an optimal policy approach. The study team is proposing a lab study and field assessment to determine how including menthol and mint e-liquids in e-liquid flavor bans or sales restrictions affects tobacco product purchasing and use among menthol cigarette smokers. At lab sessions, participants will complete the Experimental Tobacco Marketplace (ETM) task, a behavioral economics task in which they receive account balances to an online store and can buy menthol cigarettes at escalating costs or buy e-liquids, non-menthol cigarettes, or nicotine replacement gum at fixed costs. They will complete the task under four marketplace conditions: (1) only tobacco e-liquids available, (2) menthol and tobacco e-liquids available, (3) menthol, mint, and tobacco e-liquids available, and (4) tobacco, menthol, mint, fruit, dessert. During a field assessment, product choice is validated by assessing use of products purchased during the ETM task. This proposal will inform policy-makers about the impact banning menthol and mint e-liquids will have on facilitating menthol cigarette smokers switching to e-cigarettes.

Detailed description

The study team proposes to conduct a within-subjects, multi-session virtual lab study and validation field assessment to determine how the availability of menthol and mint e-liquids affects product purchasing among menthol cigarette smokers. Adult daily menthol cigarette smokers will be recruited for this study. After initial eligibility is assessed, participants will complete six virtual sessions and one field assessment to evaluate their tobacco use. Participants will be recruited from Winston-Salem, North Carolina (NC) and the surrounding area using advertisements on public transit, community flyers, and social media. Curbside visits to drop off biosamples and pickup study products will be conducted outside the Wake Forest Tobacco Control Center of Excellence located in Biotech Place in the Innovation Quarter. The study team anticipates recruiting up to 100 participants to achieve 80 completers. Equal numbers of black and white participants will be enrolled.

Conditions

Interventions

TypeNameDescription
BEHAVIORALTobacco e-liquidsMarketplace includes tobacco flavored e-liquids
BEHAVIORALMenthol and Tobacco e-liquidsMarketplace includes menthol and tobacco flavored e-liquids
BEHAVIORALMint, Menthol and Tobacco e-liquidsMarketplace includes mint, menthol and tobacco flavored e-liquids
BEHAVIORALAll e-liquid flavorsMarketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids

Timeline

Start date
2021-06-21
Primary completion
2022-12-29
Completion
2022-12-29
First posted
2021-05-10
Last updated
2024-06-26
Results posted
2024-06-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04879225. Inclusion in this directory is not an endorsement.